Tracheoesophageal Fistula Clinical Trial
Official title:
A Pilot Study: Evaluating the Safety and Feasibility of Using Autologous Adipose-Derived Stromal Vascular Fraction (SVF) for the Treatment of Aerodigestive & Enterocutaneous Fistulae in Adults
Verified date | April 2023 |
Source | Mayo Clinic |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Determine safety and feasibility of using institutionally prepared autologous, uncultured SVF on patients with aerodigestive and enterocutaneous fistulae secondary to malignancy, trauma or surgery.
Status | Withdrawn |
Enrollment | 0 |
Est. completion date | February 2028 |
Est. primary completion date | February 2027 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 90 Years |
Eligibility | Inclusion Criteria: - Adults = 18 years old - Adults = 90 years old - Fistula or sinus tract opening size between 2 mm and 15 mm in diameter (as measured by comparing its size with the open mouth of a biopsy forceps) - Inpatient or outpatient setting - Recurrent or de novo fistulas or sinus tracts - A prior diagnosis of ADF OR ECF in which the standard therapy has failed or is not applicable - Fistula or sinus tract location may include: - Tracheopharyngeal - Tracheoesophageal - Bronchoesophageal - Gastric, duodenal, jejunal, ileal, colonic or anastomotic -communicating to the skin (cutaneous) - Esophogealgastric anastomosis - Mediastinal anastomotic leak - Fistula etiology may include: - Secondary to previous malignancy with complete remission - Secondary to radiotherapy as long as complete remission for 5 years has been achieved and documented - Congenital with or without previous treatment - Secondary to surgical interventions or endoscopic therapies such as dilation and esophageal manipulation - Post prolonged tracheal intubation - Secondary to inflammatory bowel disease - Secondary to foreign body ingestion - Secondary to thoracic trauma/crush injuries - Secondary to caustic ingestion - Secondary to pneumonectomy or mechanical ventilation - Esophagomalacia - The ability of subjects to give appropriate consent or have an appropriate representative available to do so - The ability of subjects to return for follow up endoscopic assessment as established. Exclusion Criteria - Exposure to any investigational drug or procedure within 3 months prior to study entry. - Patients with allergy to fibrin glue (TISSEEL) or anesthetics - Patients with active/ongoing malignancy such as esophageal, lung, tracheal, thyroid, oropharyngeal or gastric cancer - Patients on active regimen of chemotherapy - Patients receiving radiation - Diabetics with poor glucose metabolic control exhibited by an HbA1c > 9 - If there is evidence, in endoscopy, of dysplastic-appearing mucosa such as Barrett's dysplasia near the fistula or sinus tracts, this will be excluded. Patients that require surgical intervention at the fistula or sinus tract area for any reason - BMI of <16 (may difficult lipoaspiration procedure) - Women who are pregnant or nursing or women of childbearing potential who are unwilling to maintain contraceptive therapy for the duration of the study - Clinical signs of respiratory tract or pleuro-pulmonary infections - Prolonged (> 6 months) use of steroids - Patients with fistulae or sinus tracts >15mm - Drug or alcohol dependence - Active infectious disease positive for HIV, HTLV, HBV, HCV, CMV (IgM > IgG) and/or syphilis - End of life |
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
Mayo Clinic |
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Assessment of Adverse Events from a single dose of autologous stromal vascular fraction (SVF) applied endoscopically into aerodigestive fistulae or enterocutaneous fistula [Safety and Tolerability]. | Documentation of signs of adverse reactions from intravascular application of TISEEL, including: intravascular coagulation, thromboembolic events and acute hypersensitivity reactions. Documentation of signs of increased fistula size and/or aggravation of symptoms associated with fistulous tract, including: paroxysmal cough, dysphagia, wheezing, abdominal distention, chest pain, dyspnea, pneumonia. | 5 Years | |
Primary | Assessment of Adverse Events from liposuction procedure [Safety and Tolerability]. | Signs of adverse reactions to the lipoaspiration procedure, including: allergic reaction to Hunstad solution, infection at the puncture wound site or risk of bleeding at the puncture wound site. | 5 Years | |
Secondary | Assessment of efficacy of Stromal Vascular Fraction's (SVF)'s ability to improve the success of surgical repair by fistulous tract reduction and/or closure. | Measurement and photography of the fistula in endoscopic/bronchoscopic evaluation. | 16 weeks | |
Secondary | Assessment of efficacy of Stromal Vascular Fraction's (SVF)'s ability to improve the success of surgical repair in reducing cardinal symptoms. | Documentation of reduction of cardinal symptoms by history and physical examination. | 5 Years | |
Secondary | Assessment of efficacy of Stromal Vascular Fraction's (SVF)'s ability to prevent recurrence of aerodigestive fistulae or enterocutaneous fistulae. | Documentation of fistula recurrence by long term follow-up. | 5 Years |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT03730454 -
Transanastomotic Tube for Proximal Esophageal Atresia With Distal Tracheoesophageal Fistula Repair
|
N/A | |
Recruiting |
NCT03455881 -
Phenotypic and Genetic Assessment of Tracheal and Esophageal Birth Defects in Patients
|
||
Terminated |
NCT02364843 -
A Physiological Study to Determine the Enteral Threonine Requirements in Infants Aged 1 to 6 Months
|
N/A | |
Completed |
NCT02033772 -
Prospective Data Collection of Patients < 6 Months of Age Undergoing Thoracoscopic Surgery
|
N/A |